BeiGene executive reportedly under investigation in China
Eva Yin, the chief commercial officer for Greater China at BeiGene, is reportedly under investigation by local authorities for alleged ties to an insurance fraud case while she was at AstraZeneca. The...
View ArticleLilly, J&J both unveil positive late-stage data in Crohn's disease
Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also sharing long-term data in ulcerative colitis. In the Phase 3 GRAVITI study,...
View ArticleBipartisan letter questions FDA's 'narrow' interpretation for priority review...
Sen. Tim Scott (R-SC) and Rep. Danny Davis (D-IL) are questioning the FDA's "narrow" interpretation of “active ingredient” when it comes to awarding the potentially lucrative priority review vouchers....
View ArticleWuXi AppTec is still signing on new clients despite Biosecure threat
WuXi AppTec said it is still attracting hundreds of fresh customers despite the Biosecure Act looming in the background. But a vast majority of these new clients are for early-stage services with...
View ArticleHow Nvidia plans to provide the building blocks of AI in health tech
LAS VEGAS — Nvidia’s ambitions within healthcare have a strong foothold in biopharma and life sciences. It’s now looking to grow its presence in digital health. The AI chipmaker’s healthcare strategy...
View ArticleIambic attempts to ‘break the wall’ between the lab and clinic with new AI model
Iambic Therapeutics has used its AI models to build a pipeline and put its first drug candidate in the clinic earlier this year. Now, the San Diego company is debuting a model with even bolder ...
View ArticleNovartis takes $800M MorphoSys writedown mere months after closing acquisition
Just five months after closing its $2.9 billion deal for MorphoSys, Novartis has recorded an $800 million impairment on the acquisition after a review of “certain clinical trial data,” the company said...
View ArticleCorrected: Genmab lines up T cell engager pact with Revitope
Genmab, a well-known Danish antibody biotech, is partnering with Revitope Oncology on T cell engagers, a type of cancer medicine that has become more popular this year and is now being tested in...
View ArticlePfizer raises revenue guidance by $1.5B with all eyes on performance
With Starboard Value looking over its shoulders, Pfizer has raised its earnings guidance for the year by $1.5 billion, the second time in consecutive quarters. The company now expects to earn between...
View ArticleParagon launches another company in hot PD-1xVEGF space that goes straight to...
Antibody maker Paragon Therapeutics has formed another company, this time in the bustling cancer space of PD-1xVEGF, and it will go straight onto the public markets. The new biotech, named Crescent...
View ArticlePathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AI
Chicago startup Pathos AI has completed a $62 million Series C to keep looking for Phase 1 cancer drugs that it can acquire and test in more specific patient populations, it
View ArticleGLP-1 compounding pharmacies took center stage at digital health’s biggest...
LAS VEGAS — The hottest companies at this year's annual HLTH conference weren't buzzy startups with billions in backing for a new approach to disrupt the healthcare industry. They were compounding...
View ArticleEyepoint sells $100M in shares after unveiling eye disease data for...
EyePoint Pharmaceuticals is selling $100 million worth of shares on the back of positive mid-stage data for a drug-device candidate in diabetic macular edema. The results pushed its share price up by...
View ArticleGSK buys autoimmune T cell engager for $300M upfront from Chimagen
As early data show how T cell engagers — originally developed for cancers — can potentially treat a range of autoimmune diseases, GSK is buying its own molecule from Chimagen Biosciences. The UK pharma...
View ArticleTwo type 1 diabetes patients are insulin-free after Eledon's...
Eledon Pharmaceuticals’ experimental immunosuppressant helped two patients with type 1 diabetes go insulin-free following an islet cell transplant, the company announced Tuesday. The company's stock...
View ArticleVera’s $300M offering; Abeona resubmits treatment for rare skin disease
Plus, news about Astellas, Clover, ElevateBio, Monopar, Idorsia and Neurocrine Biosciences: Vera Therapeutics plans $300M offering: The California biotech is selling shares after presenting Phase 2b...
View ArticleIn bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its...
Eli Lilly presented new data illustrating how a different dosing regimen of its Alzheimer’s drug reduced the frequency of brain swelling. The results could help Lilly argue for a change to Kisunla’s...
View ArticleNovartis highlights overall M&A track record following MorphoSys impairment
Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording an $800 million impairment to its recent MorphoSys acquisition. During...
View ArticlePacBio bets on 'inflection point' with $500 long-read genome
Pacific Biosciences says it can produce high-fidelity genetic code for as little as $500, a move that aims to reach more labs and revive the company's struggling business. The company on Tuesday...
View Article